# Immunobiology of Lung Injury and Fibrosis

> **NIH NIH R35** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $901,281

## Abstract

The overarching theme for our research program over the past 20 years has been to better understand the
etiology and pathogenesis of lung injury, repair and remodeling, with a particular interest in how the immune
response shapes pathologic and homeostatic processes in the lung. Our laboratory has contributed seminal
studies related to 1) chemokine-mediated angiogenesis in cancer and lung fibrosis, 2) eicosanoid regulation of
lung fibrosis, 3) eicosanoid regulation of innate immunity in the setting of hematopoietic stem cell
transplantation (HSCT), 4) chemokine regulation of lung fibrosis, 5) fibrocyte functions in lung fibrosis, 6)
matricellular protein regulation of lung fibrosis, 7) proteomic, microbiome and other biomarker studies in lung
fibrosis, 8) role of viral infections in “idiopathic” lung fibrosis, 9) role of viral infections in mediating pneumonitis
and fibrosis post-HSCT and 10) studies of secondary bacterial infection post-influenza. Our work has utilized
animal models to carry out mechanistic studies and has utilized patient-derived materials to confirm relevant
pathways, identify therapeutic targets and characterize novel biomarkers. Based on our previously published
observations and novel preliminary data, our laboratory is broadly focused in 4 main areas. The first is to study
innate immune signaling in regulation of secondary bacterial infections post-influenza. The second is to explore
interactions between the lung microbiome and innate signaling receptors in the pathogenesis of lung fibrosis.
The third is to explore the role of myeloid-specific heparin-binding epidermal-like growth factor (HB-EGF)
signaling in regulation of lung fibrosis. The fourth is to further understand the viral etiology and pathogenesis
of lung pneumonitis and fibrosis as a complication of HSCT. This outstanding investigator award mechanism
will allow us to extend our studies in each of these areas and will allow for mechanistic understanding of the
role of immune signaling in the pathogenesis of fibrosis, pneumonitis and lung injury, especially following viral
infection. It will also allow our laboratory to complete proof of concept and validation studies needed in both
animals and humans to advance new therapies to the clinics for treatment of lung diseases.

## Key facts

- **NIH application ID:** 10062513
- **Project number:** 5R35HL144481-03
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Bethany B. Moore
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $901,281
- **Award type:** 5
- **Project period:** 2019-01-21 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10062513

## Citation

> US National Institutes of Health, RePORTER application 10062513, Immunobiology of Lung Injury and Fibrosis (5R35HL144481-03). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10062513. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*